CD24 and neoplasm: In the urgent need to combat tumors, accelerating clinical research on CD24 is crucial, whether it is developing new antibodies to more precisely target tumor cells, studying the synergistic combination of anti-CD24 with other immunotherapies to improve overall treatment outcomes, or exploring the combination of anti-CD24 with radiochemotherapy to combat tumor resistance, these are all directions and pathways worth exploring.